Join to View Full Profile
200 Hawkins DrIowa City, IA 52242
Phone+1 319-356-2353
Fax+1 319-353-8383
Dr. Burkard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Burkard is an oncology specialist based in Iowa City, IA, with subspecialties in breast cancer and cancer genetics/cancer risk assessment. He completed his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center and his residency in internal medicine at New York Presbyterian Hospital. He obtained his medical degree from the University of Rochester School of Medicine and Dentistry. His experience includes neoplasm staging, and he has contributed to research with several publications, including studies on breast cancer and super-resolution microscopy. Dr. Burkard has also been involved in clinical trials related to cancer treatment and has received recognition such as the CMS Meaningful Use Stage 1 Certification from Epic Systems Corporation.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2004
University of Rochester School of Medicine and DentistryClass of 2002
Certifications & Licensure
IA State Medical License 2024 - 2025
WI State Medical License 2008 - 2025
NY State Medical License 2003 - 2008
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer Start of enrollment: 2010 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.Sailaja Kamaraju, Amy M Fowler, Sergey Tarima, Lubna N Chaudhary, Mark E Burkard
Clinical Breast Cancer. 2025-04-01 - Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive
Nature Medicine. 2025-03-01 - One step 4× and 12× 3D-ExM enables robust super-resolution microscopy of nanoscale cellular structures.Roshan X Norman, Yu-Chia Chen, Emma E Recchia, Jonathan Loi, Quincy Rosemarie
The Journal of Cell Biology. 2025-02-03
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
Iowa Maintains Fastest-Growing Cancer Rate as Survivor Numbers GrowFebruary 25th, 2025- Big Cancer Practice Acquisition Reflects Changing Oncology LandscapeOctober 25th, 2024
- UI Health Care Medical Center Once Again Ranked Iowa’s No. 1 Hospital by ‘US News & World Report’July 16th, 2024
- Join now to see all
Grant Support
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Exploring m6A RNA Modification in HIV-associated Cancers in Aging Populations (HIV-Associated Cancers in Aging Populations)UNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Exploring m6A RNA Modification in HIV-associated Cancers in Aging Populations (HIV-Associated Cancers in Aging Populations)UNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Exploring m6A RNA Modification in HIV-associated Cancers in Aging Populations (HIV-Associated Cancers in Aging Populations)UNIVERSITY OF IOWA2024–2026
- Exploring m6A RNA Modification in HIV-associated Cancers in Aging Populations (HIV-Associated Cancers in Aging Populations)UNIVERSITY OF IOWA2024–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
